Follicular Lymphoma

Follicular Lymphoma

Up next

Transitioning from Fellow to Attending with Dr. Laura Vater

This week’s episode we have a very special guest, friend and colleague Dr. Laura Vater joining us to talk about one of the biggest transitions in medicine—moving from fellow to attending.Dr Vater is a GI oncologist at IU, writer, and speaker. She focuses on the dignity of patient ...  Show more

ASCO 2026 Plenary: SARC-041

This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progres ...  Show more

Recommended Episodes

Episode 138: Follicular Lymphoma Series, Pt 3 - Relapsed/Refractory Management (non-cellular therapy options)
The Fellow on Call: The Heme/Onc Podcast

This week, we shift our focus to talking about relapsed/refractory follicular lymphoma. In this episode, we will specifically discuss treatment options other than cellular therapy, which will be an u ...

  Show more

Episode 136: Follicular Lymphoma Series, Pt. 1 - Introduction
The Fellow on Call: The Heme/Onc Podcast

This week, we kick off a new series, this time focusing on follicular lymphoma! This series will build on a lot of fundamentals that we discussed in our prior series. In this first episode, we start with an ...

  Show more

Episode 137: Follicular Lymphoma Series, Pt 2. - Front-line Management
The Fellow on Call: The Heme/Onc Podcast

This week, we continue our conversation on follicular lymphoma, this time focusing on front line therapy. We discuss how we approach localized and diffuse disease and the data behind why we do what we do. </ ...

  Show more

Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)
The Fellow on Call: The Heme/Onc Podcast

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ...

  Show more